Prioritizing cancer therapeutic small molecules by integrating multiple OMICS datasets

Area of Science:

• Computational biology
• Drug discovery
• Genomics

Background:

• Traditional drug discovery methods (in vivo, in vitro) are costly and time-consuming.
• The post-genomics era enables large-scale screening using OMICS data.
• Identifying effective leading compounds is critical for anti-cancer drug development.

Purpose of the Study:

• To develop a computational method for prioritizing small molecules as leading compounds.
• To integrate transcriptomics and toxicogenomics data for improved drug design.
• To reduce the time and cost associated with identifying potential anti-cancer therapeutics.

Main Methods:

• Developed a computational approach integrating transcriptomics and toxicogenomics data.
• Prioritized small molecules based on integrated OMICS data.
• Validated the method using breast and prostate cancer datasets.

Main Results:

• Identified 11 known breast cancer therapeutics within the top 100 candidates, with 2 in the top 10.
• Found 3 additional top 10 small molecules related to cancer treatment in DrugBank.
• Demonstrated superior performance compared to permutation tests, shared gene methods, and random selection in both breast and prostate cancer datasets.

Conclusions:

• The OMICS data-based method is a competitive and valuable tool for anti-cancer drug design.
• This computational strategy effectively directs experimental studies, saving time and resources.
• The method shows promise for future applications in cancer therapy development.